Bavarian Nordic Rises On First Vaccine Approval

Sheridan, Cormac
August 2013
BioWorld International;8/14/2013, Vol. 18 Issue 33, p5
The article reports on the 6.6% increase in pharmaceutical company Bavarian Nordic A/S shares. It notes that this increase resulted from European Commission's approval of Bavarian Nordic's third-generation smallpox vaccine Imnavex which is based on a modified vaccinia Ankara (MVA) vector. The product was developed by vaccine developer Kvistgaard.


Related Articles

  • Bavarian Nordic shares rise on collaboration deal with GSK.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p18 

    Reports on the collaboration between Bavarian Nordic and GlaxoSmithKline on the production and marketing of Bavarian's smallpox vaccine Imvamue. Terms of the collaborative contract; Responsibility of Bavarian for development and production of Imvamune to the U.S. government under the National...

  • Bavarian Nordic Stock Falls on Plans to Raise $50M for Vaccine. Sheridan, Cormac // BioWorld International;12/2/2009, Vol. 14 Issue 48, p1 

    This article reports on a decline in the value of stocks of Bavarian Nordic A/S in November 2009 as the company plans to raise funds to finance the development of its Imvamune next-generation smallpox vaccine. The Danish company's stocks fell more than three percent. The vaccine can be used by...

  • Bavarian Gets $83M Rights Offering For Imvamune.  // Bioworld Week;4/2/2007, Vol. 15 Issue 14, p5 

    The article reports that Kvistgard, Denmark-based Bavarian Nordic AS has reported its gross proceeds of $83.3 million from a rights offering of $1.3 million or 465 million Danish krone (DKK) shares, to be used on its smallpox vaccine development and other pipeline programs. The shares, which had...

  • Bavarian Nordic Rises on First Vaccine Approval. Sheridan, Cormac // BioWorld Today;8/8/2013, Vol. 24 Issue 151, p1 

    The article reports on the increase in shares of Bavarian Nordic A/S following news that the European Commission had approved its third-generation smallpox vaccine Imvanex. The vaccine is based on a modified vaccinia Ankara (MVA) vector. On May 30, 2013, a positive opinion was issued by the...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/26/2009, Vol. 20 Issue 164, p5 

    This section offers news briefs on the pharmaceutical industry as of August 2009. Bavarian Nordic AS of Denmark is in negotiation with the government of the U.S. to develop a freeze-dried version of its small pox vaccine Imvamune. Cellceutix Corp. of Massachusetts has acquired rights to the...

  • HHS Ordering 20 Million Doses Of Imvamune.  // Bioworld Week;4/23/2007, Vol. 15 Issue 17, p3 

    The article reports on the planned acquisition of 20 million doses of Imvamune, a third-generation smallpox vaccine from Kvisgard, Denmark-based Bavarian Nordic AS by the U.S. Department of Health and Human Services, for its strategic national stockpile in Kvisgard, Denmark. The move which is...

  • Bavarian Nordic loses smallpox vaccine case to Acambis.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p19 

    The article reports on the dismissal of Bavarian Nordic AS's claims against Acambis PLC by the Federal District Court of the District of Delaware. The court has dismissed the Danish company's claims against British biotechnology firm of unfair competition relating to virus material used to...

  • Acambis and Bavarian Nordic Vie for Smallpox Vaccine Contract. Bush, Laura // Pharmaceutical Technology;Sep2005, Vol. 29 Issue 9, p24 

    Reports on the issuance of a request for proposals by the U.S. Department of Health and Human Services to acquire the doses of modified vaccinia Ankara (MVA) vaccine, a highly attenuated live smallpox vaccine. Competition between pharmaceutical firms Acambis PLC and Bavarian Nordic AS for the...

  • Other News to Note.  // BioWorld International;11/2/2011, Vol. 16 Issue 44, p3 

    This section offers news briefs pertaining to the global pharmaceutical industry, as of November 2011, including the sublicense agreement between France's Atlab Pharma SAS and New York's BZL Biologics LLC to develop a prostate cancer treatment, the payment received by Bavarian Nordic A/S of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics